Septerna, Inc. (SEPN) stock
SEPNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 9, 2026Score 8/30195% above fair value
$42.60+0.74 (+1.77%)
Close on Nov 13, 2026Market cap $1.99BP/E –Yield –
Septerna ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Septerna's ebitda for the twelve months ending Sep 30, 2026 was -$71.79M. For fiscal 2025 it was -$66.70M.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$66.70M | – |
| FY2024 | Dec 31, 2024 | -$79.42M | -2862.5% |
| FY2023 | Dec 31, 2023 | $2.88M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$26.83M | -990.1% |
| Q2 FY2026 | Jun 30, 2026 | -$16.44M | – |
| Q1 FY2026 | Mar 31, 2026 | -$12.90M | – |
| Q4 FY2025 | Dec 31, 2025 | -$15.62M | – |
| Q3 FY2025 | Sep 30, 2025 | $3.01M | – |
| Q2 FY2025 | Jun 30, 2025 | -$28.58M | – |
| Q1 FY2025 | Mar 31, 2025 | -$25.51M | – |
| Q4 FY2024 | Dec 31, 2024 | -$24.32M | -170.5% |
| Q3 FY2024 | Sep 30, 2024 | -$22.15M | – |
| Q2 FY2024 | Jun 30, 2024 | -$17.77M | – |
| Q1 FY2024 | Mar 31, 2024 | -$15.19M | – |
| Q4 FY2023 | Dec 31, 2023 | $34.52M | – |
| Q3 FY2023 | Sep 30, 2023 | -$11.84M | – |
See a number that looks wrong?